HHS Secretary Robert F. Kennedy Jr. asked the FDA "to review the latest data on mifepristone ," but experts say concerns about the abortion pill's safety are misguided.

The Food and Drug Administration on Monday named a longtime pharmaceutical executive to run the agency's drug program, the latest in a string of leadership changes at the agency.

A top official at the U.S. Food and Drug Administration (FDA) confirmed on Monday that the organization will conduct a review of the abortion drug mifepristone following several recent studies ...

Pro-life medical groups are urging Health and Human Services Secretary Robert Kennedy Jr. to reexamine the FDA’s broad ...

More than 50 biotech leaders and investors are urging the FDA to disregard a methodologically flawed report on mifepristone.

By questioning the FDA's authority to regulate an abortion drug, ... "The FDA approval process is one that is based on extensive, evidence-based, scientific review of efficacy and safety.

Emergency room visits after abortion-drug use were 79 percent more likely to be miscoded as natural miscarriages compared with those following surgical abortions, according to a new study ...

As abortion-rights activists have pushed to loosen the FDA safety protocols, pro-life advocates have begun pushing in the opposite direction, rightly noting the potentially grave hazards to women ...

A package of mifepristone abortion pills is shown on the left shortly after the drug was approved by the FDA in 2000, while a Viagra pill and packaging are pictured on the right in 1999.

Beyond the implications for abortion, the medication abortion case also has consequences for what kind of authority and discretion the FDA has to determine a drug’s safety and appropriate rules ...

Appeals court embraces abortion-pill limits, sets up Supreme Court review. The Supreme Court has ruled that mifepristone, a key abortion drug, will remain available for now under existing rules ...